Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9036055 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2PKMCYP3A4CYP2C19GAA | |
| SCHEMBL738198 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2PKMCYP3A4CYP2C19GAA | |
| SCHEMBL8488469 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2PKMCYP3A4CYP2C19GAA | |
| SCHEMBL8487298 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2PKMCYP3A4CYP2C19GAA | |
| SCHEMBL2115037 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2PKMCYP3A4CYP2C19GAA | |
| SCHEMBL3054776 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2PKMCYP3A4CYP2C19GAA | |
| SCHEMBL13912231 | 0.82 | SMN1; SMN2 (0.58) | SMN1; SMN2PKMCYP3A4CYP2C19GAA | |
| SCHEMBL762984 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2PKMCYP3A4CYP2C19GAA | |
| SCHEMBL5206904 | 0.81 | SMN1; SMN2 (0.47) | SMN1; SMN2PKMCYP3A4CYP2C19GAA | |
| SCHEMBL18380804 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2PKMCYP3A4CYP2C19GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276433-A1 | Hydrazone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | ELAN PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| EP-1612204-A1 | HYDRAZONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
| WO-2003103652-A1 | METHODS OF TREATING ALZHEIMER’S DISEASE USING AROMATICALLY SUBSTITUTED ω-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-5958837-A | 2-(PHENYLMETHOXY OR CARBONYLOXY-(1,4-PHENYLENE)-),3-HALO,5-HALOALKYLPYRIDINES; HERBICIDES EFFECTING DESICCATION AND DEFOLIATION OF PLANTS; GOOD ACTIVITY AND BETTER TAILORED CONTROL OF WEEDS | BASF AKTIENGESELLSCHAFT (DE) | 1999-09-28 | — | — | US | disclosed |
| EP-0802904-B1 | SUBSTITUTED 2-PHENYLPYRIDINES AS HERBICIDES | BASF AG (DE) | 1998-09-09 | — | — | EP | disclosed |
| CN-1172477-A | Substituted 2 -phenylpyridines as herbicides | BASF AG (DE) | 1998-02-04 | — | — | CN | disclosed |
| US-5641778-A | EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
| WO-1996021647-A1 | SUBSTITUTED 2-PHENYLPYRIDINES AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1996-07-18 | — | — | WO | disclosed |
| EP-0716077-A1 | Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors | CIBA-GEIGY AG (CH) | 1996-06-12 | — | — | EP | disclosed |
| CN-1114834-A | antidiabetic agent | OTSUKA PHARMA CO LTD (JP) | 1996-01-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | APP, BACE1, BACE2 | SMN1; SMN2 1043/4885PKM 4344/4885CYP3A4 2565/4885 |
| US-20060276433-A1 | Hydrazone derivative | APP, PRNP, HTT | SMN1; SMN2 2146/4885PKM 3411/4885CYP3A4 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.